Advertisement
Advertisement

MREO

MREO logo

Mereo BioPharma Group plc - ADR

0.30
USD
Sponsored
-0.01
-3.14%
Aug 07, 15:58 UTC -4
Closed
exchange

After-Market

0.30

0.00
+1.25%

Mereo BioPharma Group plc - ADR Profile

About

Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company's rare disease product candidates, setrusumab for the treatment of osteogenesis imperfecta and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease. Mereo BioPharma Group plc is based in LONDON.

Info & Links

CEO

Denise Scots-Knight

Headquarters

ONE CAVENDISH PLACE, FOURTH FLOOR
LONDON, X0 W1G 0QF, UNITED KINGDOM

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.mereobiopharma.com

Auditor

PricewaterhouseCoopers LLP

Share holders

--

Employees

39

Mereo BioPharma Group plc - ADR Statistics

Valuation Measures

Market Capitalization2

47.89M

Enterprise Value

11.66M

Enterprise Value/EBITDA(ttm)

-0.32

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

1.43

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

18.40%

Operating Margin(ttm)

--

Profit Margin(ttm)

-730.80%

Return on Equity(ttm)

-81.28%

Return on Invested Capital(ttm)

-79.75%

Return on Assets(ttm)

-70.45%

Income Statement

Revenue(ttm)

500.00K

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

367.00K

EBITDA(ttm)3

-37.02M

Net Income Available to Common(ttm)

-35.71M

Diluted EPS(ttm)

-0.05

Share Statistics

Beta (5Y Monthly)

0.36

52-Week Change

-81.25%

S&P 500 52-Week Change

21.41%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

159.62M

Dividend Yield

0.00%

Float4

149.24M

% Held by Insiders

6.50%

% Held by Institutions

62.83%

Balance Sheet

Total Cash(mrq)

36.22M

Total Cash Per Share(mrq)

0.23

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

6.48%

Quick Ratio(mrq)

6.48%

Book Value Per Share(mrq)

0.21

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.03

Free Cash Flow(ytd)

-4.31M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement